Torrent Pharmaceuticals Ltd stands as one of India's prominent pharmaceutical companies, currently ranked 7th in the Indian Pharmaceuticals Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology. The flagship company of the Torrent Group, is one of the leading Pharma companies in India, with a market capitalization of ₹1,13,983 Crore as of March 2025.
Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed Torrent Pharmaceuticals in 1971. The company has been pioneering the concept of niche marketing in the Indian pharmaceutical industry and has evolved into a major player in the domestic and international pharmaceutical markets.
Torrent Pharmaceuticals has 17,271 total employees and operates from its headquarters in Ahmedabad, Gujarat. The company has built a strong reputation for delivering high-quality pharmaceutical products across multiple therapeutic segments.
Torrent Pharmaceuticals operates through a comprehensive manufacturing network with eight manufacturing facilities in India, at Indrad, Dahej, and Bileshwarpura in Gujarat; Baddi in Himachal Pradesh; Sikkim; Visakhapatnam in Andhra Pradesh; and Pithampur in Madhya Pradesh. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.
The company's business model focuses on the manufacturing, marketing, and distribution of branded generics and generic pharmaceutical products. Generic Formulation Business is the company's single segment, which encompasses both branded and generic pharmaceutical formulations.
Torrent Pharmaceuticals has established itself as a leader in multiple therapeutic segments. The company is among the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), women healthcare (WHC), Vitamins Minerals & Nutrients (VMN), and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
The company's product portfolio includes cardiovascular drugs, antibiotics, anti-diabetic drugs, anti-inflammatory drugs, and anti-infective drugs. Popular brands include Cadila, Torleva, Torlip, and Torleva XR.
Torrent Pharmaceuticals has built a strong international presence, with presence in more than 50 countries. The Company is ranked first amongst Indian Companies for having largest market share in Brazil and Germany. The Company has presence in more than 40 countries and is ranked No. 1 among the Indian pharma Companies in Brazil, Germany and Philippines.
The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany, and Brazil.
Torrent Pharmaceuticals has demonstrated consistent financial performance in recent periods. For the full year, net profit rose 15.40% to ₹1,911.00 Crore in the year ended March 2025, as against ₹1,656.00 Crore during the previous year ended March 2024. Sales rose 7.15% to ₹11,317.00 Crore in the year ended March 2025, as against ₹10,562.00 Crore during the previous year ended March 2024.
For the quarter ended March 2025, net profit of Torrent Pharmaceuticals rose 10.91% to ₹498.00 Crore in the quarter ended March 2025, as against ₹449.00 Crore during the previous quarter ended March 2024. Sales rose 7.94% to ₹2,909.00 Crore in the quarter ended March 2025, as against ₹2,695.00 Crore during the previous quarter ended March 2024.
The company maintains a strong focus on research and development with a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million. Torrent has 782 scientists and 167 support staff in its R&D activities. The company spent INR247.3 million on research and development expenses in FY2024, which as a percentage of revenue, stood at 0.2%.
The company maintains good corporate governance practices with promoter holding in Torrent Pharmaceuticals Ltd at 68.31% as of March 2025. The company has been maintaining a healthy dividend payout of 57.9% and recently announced an interim dividend of ₹26 per equity share.
Torrent Pharmaceuticals has pursued strategic acquisitions to strengthen its market position:
* In 2013, Torrent Pharma acquired the India formulations business of Elder Pharmaceuticals for ₹2,004 Crore.
* In 2017, Torrent Pharma acquired the domestic business of Unichem Laboratories for ₹3,600 Crore.
* In 2022, the company acquired skincare manufacturer Curatio Healthcare for ₹2,000 Crore.
Torrent Pharmaceuticals continues to maintain its strong market position in the Indian pharmaceutical industry. 64.29% of analysts recommend a 'BUY' rating for Torrent Pharmaceuticals Ltd with a target price of ₹3,593.68, a slight upside of 12.75% compared to the current price. The company's diversified portfolio, strong manufacturing capabilities, and international presence position it well for continued growth in the pharmaceutical sector.
